Despite the retraction of one study suggesting that elevated pre-treatment free IGF-I levels were associated with NSCLC patient response to figitumumab ([Retraction PMID: 21102589]), additional evidence supporting these findings has been published. The gene discussed is IGF1; the disease is non-small cell lung carcinoma.